{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:41:42Z","timestamp":1784238102378,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00228-023-03557-6","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T14:02:35Z","timestamp":1693576955000},"page":"1443-1452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review"],"prefix":"10.1007","volume":"79","author":[{"given":"Jalal","family":"Arabloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samad","family":"Azari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Abolghasem","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u202cSeyed Jafar","family":"Ehsanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"2","key":"3557_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13696998.2018.1542599","volume":"22","author":"TE Delea","year":"2019","unstructured":"Delea TE, Sharma A, Grossman A et al (2019) Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma. J Med Econ 22(2):117\u2013130","journal-title":"J Med Econ"},{"issue":"1","key":"3557_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","volume":"15","author":"J Huang","year":"2022","unstructured":"Huang J, Pang WS, Lok V et al (2022) Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol 15(1):57","journal-title":"J Hematol Oncol"},{"key":"#cr-split#-3557_CR3.1","unstructured":"ACS About Hodgkin Lymphoma (2022) [Internet]"},{"key":"#cr-split#-3557_CR3.2","unstructured":"[cited 2022 Aug 9]. American Cancer Society. Available from: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8649.00.pdf"},{"key":"3557_CR4","doi-asserted-by":"crossref","unstructured":"Huntington SF, Von Keudell GR, Davidoff AJ et al (2018) Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III\/IV Hodgkin lymphoma. J Clin Oncol 36(15)","DOI":"10.1200\/JCO.2018.36.15_suppl.6609"},{"issue":"16","key":"3557_CR5","first-page":"1560","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Radford JA (2018) Brentuximab vedotin for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378(16):1560\u20131561","journal-title":"N Engl J Med"},{"issue":"25","key":"3557_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374(25):2419\u20132429","journal-title":"N Engl J Med"},{"issue":"4","key":"3557_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ajh.24272","volume":"91","author":"SM Ansell","year":"2016","unstructured":"Ansell SM (2016) Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91(4):434\u2013442","journal-title":"Am J Hematol"},{"key":"#cr-split#-3557_CR8.1","unstructured":"FDA Products on BLA 125388 (2011) [Internet]"},{"key":"#cr-split#-3557_CR8.2","unstructured":"[cited 2022 Aug 9]. US Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125388"},{"key":"3557_CR9","unstructured":"Street Insider. Seattle Genetics (SGEN) Granted Approval of ADCETRIS (Brentuximab Vedotin) (2017; [Internet]; [cited 2022 Aug 9]. Street Insider. Available from: https:\/\/www.streetinsider.com\/Corporate+News\/Seattle+Genetics+%28SGEN%29+Granted+Approval+of+ADCETRIS+%28Brentuximab+Vedotin%29\/13125348.html"},{"issue":"13","key":"3557_CR10","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI et al (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348\u20131356","journal-title":"Lancet Oncol"},{"issue":"18","key":"3557_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183","journal-title":"J Clin Oncol"},{"issue":"7","key":"3557_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)","journal-title":"PLoS Med"},{"key":"#cr-split#-3557_CR13.1","unstructured":"The Campbell and Cochrane Economics Methods Group (CCEMG) & Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) (2019) [Internet]"},{"key":"#cr-split#-3557_CR13.2","unstructured":"[cited 2022 Aug 9]. CCEMG - EPPI-Centre Cost Converter. Available from: https:\/\/eppi.ioe.ac.uk\/costconversion\/"},{"issue":"1","key":"3557_CR14","first-page":"53","volume":"9","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ et al (2003) Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 9(1):53\u201361","journal-title":"J Manag Care Pharm"},{"issue":"19","key":"3557_CR15","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1002\/cncr.30818","volume":"123","author":"L Hui","year":"2017","unstructured":"Hui L, von Keudell G, Wang R et al (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123(19):3763\u20133771","journal-title":"Cancer"},{"issue":"1","key":"3557_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13696998.2018.1534738","volume":"22","author":"S Large","year":"2019","unstructured":"Large S, Hettle R, Balakumaran A et al (2019) Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin\u2019s lymphoma: a United States payer perspective. J Med Econ 22(1):16\u201325","journal-title":"J Med Econ"},{"issue":"1","key":"3557_CR17","first-page":"e6","volume":"24","author":"V Babashov","year":"2017","unstructured":"Babashov V, Begen MA, Mangel J et al (2017) Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma. Cancer 24(1):e6\u2013e14","journal-title":"Cancer"},{"key":"3557_CR18","doi-asserted-by":"crossref","unstructured":"Raymakers AJN, Costa S, Cameron D et al (2020) Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin\u2019s lymphoma: a probabilistic analysis. BMC Cancer 20(1)","DOI":"10.1186\/s12885-020-07374-3"},{"issue":"2","key":"3557_CR19","doi-asserted-by":"publisher","first-page":"E146","DOI":"10.1016\/S2352-3026(19)30218-2","volume":"7","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Chan K, Cheung MC et al (2020) Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol 7(2):E146\u2013E156","journal-title":"Lancet Haematol"},{"issue":"1","key":"3557_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/13696998.2016.1219358","volume":"20","author":"C Parker","year":"2017","unstructured":"Parker C, Woods B, Eaton J et al (2017) Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland [Article]. J Med Econ 20(1):8\u201318","journal-title":"J Med Econ"},{"issue":"4","key":"3557_CR21","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.1002\/ijc.29105","volume":"136","author":"P Hanly","year":"2015","unstructured":"Hanly P, Soerjomataram I, Sharp L (2015) Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in E urope. Int J Cancer 136(4):E136\u2013E145","journal-title":"Int J Cancer"},{"issue":"7","key":"3557_CR22","doi-asserted-by":"publisher","first-page":"A681","DOI":"10.1016\/j.jval.2015.09.2026","volume":"18","author":"S Cote","year":"2015","unstructured":"Cote S, Gaudig M, Nielsen S et al (2015) Challenges for assessing the economic value of orphan drugs-a literature review of current and alternative approaches. Value Health 18(7):A681","journal-title":"Value Health"},{"issue":"3","key":"3557_CR23","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.jval.2014.03.041","volume":"17","author":"G Stewart","year":"2014","unstructured":"Stewart G, Eddowes L, Hamerslag L et al (2014) The impact of NICE\u2019s end-of-life threshold on patient access to new cancer therapies in England and Wales. Value Health 17(3):A6","journal-title":"Value Health"},{"key":"#cr-split#-3557_CR24.1","unstructured":"NICE Appraising lifeextending, end of life treatments (2009) [Internet]"},{"key":"#cr-split#-3557_CR24.2","unstructured":"[cited 2022 Aug 9]. National Institute for Health and Care Excellence. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-tag387\/documents\/appraising-life-extending-end-of-life-treatments-paper2"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03557-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:03:37Z","timestamp":1698735817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03557-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03557-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The present study was approved by Ethical Committee at Iran University of Medical Sciences (ethical approval reference number: IR.IUMS.REC.1400.942). Due to the nature of the systematic review design employed in this study, the requirement for obtaining consent to participate was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}